Vaccines

This is the first authorized COVID-19 vaccine that was developed by a Canadian-based company, and the first that used a plant-based protein technology.

CDC expands recommended timeline between second and third COVID-19 vaccine to 8 weeks for people 12 years and older, especially for young men, to reduce the risk of myocarditis.

Pfizer’s TicoVac vaccine was developed to immunize young children and adults to prevent Tick-Borne Encephalitis.

Infection-acquired immunity to SARS-CoV-2 remains higher for longer when followed by vaccination.

The companies plan to seek regulatory authorization for the vaccine both in the US and Europe.

A clinician offers his perspective on how the virus is behaving and the role that vaccines and therapies will play.

Moderna was endorsed to begin phase 3 clinical trials for mRNA-1345, what could be the first respiratory syncytial virus (RSV) vaccine.

An Israeli study found COVID-19 reinfection was "relatively rare," and previously infected persons who also received at least 1 dose of the Pfizer-BioNTech mRNA vaccine had an 82% reduced risk of reinfection.

Study highlights elevated levels of antibody response in those with history of COVID-19.

COVID-19 mRNA vaccine effectiveness wanes even faster during Omicron than during Delta variant predominance, but a booster dose still provides lasting defense against COVID-19 hospitalization and death.

A preprint study shows the variant is resistant to some monoclonal antibodies and vaccines.

Regular symptom screening revealed completely asymptomatic COVID-19 infection is highly unlikely among unvaccinated people.

The varicella zoster (chickenpox) virus has been essentially eradicated thanks to the vaccine developed by Japanese virologist Dr. Michiaki Takahashi, who would have been 94 years old today.

Investigators looked at full vaccination and booster dose observational data to offer some insights on protection and breakthrough infections.

The idea of a future with COVID-19 is settling in, and building strategies that improve quality of life as we live with this viral disease are paramount.

In a study of people living with HIV in Taiwan, COVID-19 vaccination was highly effective when implemented alongside non-pharmaceutical interventions.

A research agenda focusing on breakthrough infections, reinfections, severity, and sequelae is needed to inform clinical practice when COVID-19 emphasis shifts from eradication to living with the disease.

Pfizer-BioNTech previously asked for FDA approval to administer its COVID-19 vaccine in children 6 months-4 years of age, but has deferred the request after reviewing more data.

Their investigational vaccine, NVX-CoV2373, demonstrated 82% efficacy against the Delta variant in participants 12-17 years old.

A study looked at COVID-19 vaccination rates and new COVID-19 infections across US counties during the Delta surge last summer. Many of the highly infected counties were considered rural, highlighting some of the vaccination challenges surrounding these areas.

COVID-19 vaccination rates were higher in counties with more primary care physicians, suggesting doctors are in unique positions of trust with their patients and can encourage vaccination.

A process known as thin film freezing can convert existing therapies into powder that offers another delivery solution and may help alleviate storage challenges in developing countries.

Trying to increase COVID-19 vaccination rates in these populations has been challenging. In an attempt to do so, a randomized clinical trial across 133 skilled nursing facilities (SNFs) was performed.

Intranasal COVID-19 vaccines aren’t just needle and pain-free—they may also be more effective at protecting against current and future variants.

Omicron's numerous spike protein mutations caused mass concern, but one research team hypothesizes that its mutations are largely documented and thus susceptible to COVID-19 vaccination.

A recent study in Guangdong, China, confirmed vaccine effectiveness of inactivated COVID-19 vaccines against the Delta variant of COVID-19.

Not all people unvaccinated against COVID-19 people are actively avoiding the vaccine. A new study shows that Black people were vaccinated at lower rates than White people in the US early on, even after they indicated they were willing to get the shot. The study’s authors explain the reasons behind this.

During spring 2021, when Alpha was the dominant COVID-19 variant, a midsized Midwestern university’s vaccination initiative was associated with a significant decrease in COVID-19 infections.

Low COVID-19 vaccination rates among Hispanic populations may be due to limited vaccine information available in Spanish.

The company recently submitted its data to the federal regulatory authorities for an Emergency Use Authorization of its COVID-19 vaccine, NVX-CoV2373. As it's time to think about this potential vaccine being available in the US, clinicians offer some insights and perspective on it.